Tempest Therapeutics (TPST) Other financing activities (2018 - 2025)
Tempest Therapeutics (TPST) posted Other financing activities of -$1.8 million for Q4 2025, down 199.29% sequentially from $1.8 million in Q3 2025, and down 181000.0% YoY from N/an in Q4 2024.
Tempest Therapeutics (TPST) Other financing activities (2018 - 2025) Analysis & Trends
Tempest Therapeutics has reported Other financing activities for 7 years, with the latest figure at -$1.8 million in Q4 2025.
- Quarterly Other financing activities fell 181000.0% year-over-year to -$1.8 million in Q4 2025, while the trailing twelve-month figure through Dec 2025 was $47000.0 (down 84.69% YoY) and the FY2025 annual result came in at $47000.0, down 84.69% from the prior year.
- Other financing activities slipped to -$1.8 million in Q4 2025 per TPST's latest filing, from $1.8 million in the prior quarter.
- Over five years, Other financing activities peaked at $7.3 million in Q2 2022 and troughed at -$1.8 million in Q4 2025.
- A 4-year average of $553071.4 and a median of $18500.0 in 2021 frame the typical range for Other financing activities.
- The sharpest annual moves came in 2022 and 2025: Other financing activities jumped 242800.0% in 2022, then sank 181000.0% in 2025.
- Over 4 years, Other financing activities stood at $42000.0 in 2021, then plunged by 97.62% to $1000.0 in 2022, then slumped by 200.0% to -$1000.0 in 2024, then tumbled by 181000.0% to -$1.8 million in 2025.
- According to Business Quant data, Other financing activities over the past three periods registered -$1.8 million, $1.8 million, and $34000.0 for Q4 2025, Q3 2025, and Q1 2025 respectively.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) |
|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 137.11 Bn | 129.26 Bn | 2.84 Bn |
| 2 | Regeneron Pharmaceuticals | 84.98 Bn | 76.99 Bn | 3.93 Bn |
| 3 | Argenx Se | 64.52 Bn | 59.33 Bn | 1.37 Bn |
| 4 | Moderna | 53.23 Bn | 48.09 Bn | 52.00 Mn |
| 5 | BeOne Medicines | 41.23 Bn | 36.14 Bn | 1.53 Bn |
| 6 | Alnylam Pharmaceuticals | 30.65 Bn | 27.34 Bn | 992.69 Mn |
| 7 | Insmed | 27.15 Bn | 25.99 Bn | 358.27 Mn |
| 8 | Royalty Pharma | 26.98 Bn | 26.14 Bn | - |
| 9 | BioNTech SE | 26.78 Bn | 8.39 Bn | 668.28 Mn |
| 10 | Tempest Therapeutics | 4.23 Mn | 3.43 Mn | - |
Historic Data
Download Data| Date | Value |
|---|---|
| Dec 31, 2025 | -1.81 Mn |
| Dec 31, 2025 | -1.81 Mn |
| Sep 30, 2025 | 1.82 Mn |
| Sep 30, 2025 | 1.82 Mn |
| Mar 31, 2025 | 34,000.00 |
| Mar 31, 2025 | 34,000.00 |
| Dec 31, 2024 | -1,000.00 |
| Dec 31, 2024 | -1,000.00 |
| Sep 30, 2024 | 308,000.00 |
| Sep 30, 2024 | 308,000.00 |
| Jun 30, 2024 | -197,000.00 |
| Jun 30, 2024 | -197,000.00 |
| Mar 31, 2024 | 197,000.00 |
| Mar 31, 2024 | 197,000.00 |
| Dec 31, 2022 | 1,000.00 |
| Dec 31, 2022 | 1,000.00 |
| Sep 30, 2022 | -1,000.00 |
| Sep 30, 2022 | -1,000.00 |
| Jun 30, 2022 | 7.28 Mn |
| Jun 30, 2022 | 7.28 Mn |